公开(公告)号：WO2020023268A1

公开(公告)日：2020-01-30

申请号：PCT/US2019/042234

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： YU, Xin ,  OUYANG, Wenjun ,  LI, Chi-Ming Kevin ,  EGEN, Jackson Graeme ,  YOON, Oh Kyu ,  DRIVER, Ian Halsey ,  TAKENAKA, Shunsuke ,  THOMSON, Christy Ann ,  WANG, Hongyu

IPC: C07K16/28 ,  A61K39/395

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.